A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3
Young-Chul Park(Bioleaders (South Korea)), Jae Kwan Lee(Korea University Medical Center), Moon‐Hee Sung(Kookmin University), Jong Sup Park(Catholic University of Korea), Tae Jin Kim(Konkuk University), Chi‐Heum Cho(Keimyung University), Hong-Gyu Park(Bioleaders (South Korea)), Yung‐Taek Ouh(Korea University)
Cited by 37
Related Papers
Methionine consumption by cancer cells drives a progressive upregulation of PD-1 expression in CD4 T cells
|Nature Communications|2023|71
Interleukin-6 expression by interactions between gynecologic cancer cells and human mesenchymal stem cells promotes epithelial-mesenchymal transition
|International Journal of Oncology|2015|63
Preeclampsia: A risk factor for gestational diabetes mellitus in subsequent pregnancy
|PLoS ONE|2017|57
Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014–2016
|Journal of Gynecologic Oncology|2017|53
Risk factors for type-specific persistence of high-risk human papillomavirus and residual/recurrent cervical intraepithelial neoplasia after surgical treatment
|Obstetrics & Gynecology Science|2020|51